Therapy Areas: Inflammatory Diseases
Cortexyme's Approach to Addressing a Key Underlying Cause of Alzheimer's Detailed at Alzheimer's Association International Conference 2019
19 July 2019 - - US-based biopharmaceutical company Cortexyme, Inc. (NASDAQ: CRTX) has presented clinical data that supports its ongoing work to pioneer a novel, disease-modifying therapeutic approach...
PureTech Health acquires and plans to develop LYT-100
19 July 2019 - PureTech Health, an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut axis, has acquired and is planning to develop a clinical-stage...
Pandion Therapeutics Names Kakkar as Chief Executive Officer
18 July 2019 - - US-based biotechnology company Pandion Therapeutics, Inc has appointed Rahul Kakkar, MD, FACC as chief executive officer and as a member of the company's board of directors, the ...
PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
18 July 2019 - - UK-based biopharmaceutical company PureTech Health plc (LSE: PRTC) has acquired and plans to develop a clinical-stage product candidate for the potential treatment of lymphatic and im...
Sosei reports FDA approval for APP13007 IND for first-in-human (FIH) clinical trial in the US
18 July 2019 - Biopharmaceutical company Sosei Group Corporation (TSE:4565) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for the Investigational New Dru...
Parvus Therapeutics Names Rienhoff as Chairman
17 July 2019 - - Canadian biopharmaceutical company Parvus Therapeutics has appointed Hugh Young Rienhoff, Jr., M.D., as chairman of the board, Charles A. Johnson, M.D., to the board of directors, and...
Related Headlines

Gilead and Galapagos Enter 10-Year Research and Development Collaboration

Recursion Pharmaceuticals Secures USD 121m in Series C Financing

Bayer wins US FDA approval for Gadato to assess myocardial perfusion and late gadolinium enhancement in adult patients with CAD

Gilead Sciences, Renown Institute for Health Innovation Team to Advance Understanding of Nonalcoholic Steatohepatitis

Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology

CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

RAPT Therapeutics Announces Promotion of Key Research and Development Senior Leaders

RAPT Therapeutics Names Guttman-Yassky to Scientific Advisory Board

Cyxone announces submission of first RA application for clinical phase IIb trial with Rabeximod

Pfizer Touts Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis

Martin Edwards Elected as Chair of KalVista Pharmaceuticals Board of Directors

Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis R and D Pipeline with New First-in-Class Compound from Yuhan Corp.

Bicycle Therapeutics Touts Positive Topline Results from Oxurion's Phase I Trial Using a Novel Bicycle-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

GSK starts phase III clinical development programme with otilimab

Grifols wins FDA approval of Xembify 20% subcutaneous immunoglobulin for treating primary immunodeficiencies